[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wenjin Yin\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":118},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,62,82,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100506567","capecitabine-and-cyclophosphamide-xc-as-maintenance-therapy-for-advanced-breast-cancer-100506567",false,"NCT05876065","Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer","Efficacy and Safety of Capecitabine and Cyclophosphamide (XC) Versus Physician's Choice as Maintenance Therapy for Advanced Breast Cancer: a Randomized, Controlled, Open-label Clinical Trial","Inclusion Criteria:\n\n* Female, age≥18 years old\n* ECOG≤2\n* Pathologically confirmed primary breast cancer, with pathologically or radiologically confirmed recurrent or metastatic lesions\n* HR+\u002FHER2+ or HR-\u002FHER2+ or HR-\u002FHER2-\n* At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1\n* Disease control (complete response + partial response + stable disease) after salvage treatment\n* Expected survival ≥6 months\n* Adequate organ function\n\nExclusion Criteria:\n\n* during pregnancy and lactation\n* Patients with central nervous system metastasis","FEMALE","18 Years",{"count":19,"type":20},86,"ESTIMATED","INTERVENTIONAL",[23],"NA","To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.",[26],"Advanced Breast Cancer","RECRUITING","2026-08-17",{"date":30,"type":31},"2026-08-19","ACTUAL",{"date":33,"type":31},"2023-06-01",{"date":35,"type":20},"2028-02",{"name":37,"class":38},"Wenjin Yin","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":39},"100606800","trastuzumab-deruxtecan-in-advanced-breast-cancer-100606800","NCT07180264","Trastuzumab Deruxtecan in Advanced Breast Cancer","Trastuzumab Deruxtecan in Patients With Advanced Breast Cancer: a Real-world Study","Inclusion Criteria:\n\n* Aged ≥18 and older\n* Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan\n* ECOG 0-1\n\nExclusion Criteria:\n\n* During pregnancy and lactation","ALL",{"count":49,"type":20},118,"4 Years","OBSERVATIONAL","To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.",[26],"2025-11-16",{"date":56,"type":31},"2025-11-18",{"date":58,"type":31},"2025-08-28",{"date":60,"type":20},"2029-02",{"name":37,"class":38},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":39},"100606792","phase-2-iparomlimab-and-tuvonralimab-ql1706-in-patients-with-hr-positive-her2-negative-advanced-breast-cancer-100606792","NCT07180160","Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer","Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: a Prospective, Randomised, Controlled, Multicentre Clinical Trial","ITHRAN","Inclusion Criteria:\n\n* Female, age≥18 years old\n* Expected survival ≥12 weeks\n* ECOG 0-1\n* Pathologically confirmed recurrent or metastatic breast cancer not amenable to curative surgery\n* ER and\u002For PR positive, HER2 negative\n* At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1\n* Previously treated with ≤2 lines chemotherapy for advanced disease; previously treated with ≤2 CDK4\u002F6 inhibitors\n* Adequate organ function\n\nExclusion Criteria:\n\n* During pregnancy and lactation\n* Patients with central nervous system metastasis",{"count":71,"type":20},123,[73],"PHASE2","This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative advanced breast cancer.",[26],{"date":56,"type":31},{"date":78,"type":31},"2025-09-25",{"date":80,"type":20},"2028-03",{"name":37,"class":38},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":39},"100606786","phase-2-continuous-or-intermittent-pyrotinib-for-her2-positive-advanced-breast-cancer-100606786","NCT07180082","Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer","Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer: a Prospective, Randomized, Controlled, Multicentre Clinical Trial","CORIN-PYRA","Inclusion Criteria:\n\n* Age≥18 years old\n* Pathologically confirmed advanced or locally advanced breast cancer not amenable to curative surgery\n* Pathologically confirmed HER2+ at least once for either primary or metastatic lesion\n* Previously treated with any number of lines for advanced disease and eligible for a pyrotinib-containing regimen at the discretion of physician\n* At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1\n* ECOG 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* During pregnancy and lactation\n* Difficulties with pyrotinib administration or absorption",{"count":91,"type":20},186,[73],"This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.",[26],{"date":56,"type":31},{"date":58,"type":31},{"date":98,"type":20},"2029-09",{"name":37,"class":38},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":115,"leadSponsor":117,"locationsCount":39},"100606784","adjuvant-cdk46-inhibitor-use-in-hrher2--breast-cancer-100606784","NCT07180056","Adjuvant CDK4\u002F6 Inhibitor Use in HR+\u002FHER2- Breast Cancer","Efficacy and Safety of Adjuvant CDK4\u002F6 Inhibitors in Patients With Hormone Receptor-positive\u002FHuman Epidermal Growth Factor Receptor 2-negative Breast Cancer: a Real-world Study","Inclusion Criteria:\n\n* Aged ≥18 and older\n* Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence\n* HR+\u002FHER2-\n* ECOG 0-3\n* Subjects meeting current guideline recommendations and planning to receive adjuvant CDK4\u002F6 inhibitors\n\nExclusion Criteria:\n\n* During pregnancy or lactation\n* Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption",{"count":108,"type":20},229,"To evaluate the efficacy and safety of adjuvant CDK4\u002F6 inhibitors in patients with hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative breast cancer.",[111],"Breast Cancer",{"date":113,"type":31},"2025-11-19",{"date":58,"type":31},{"date":116,"type":20},"2033-02",{"name":37,"class":38},""]